Registry-listed formulations

proxymetacaine · mesh:C005717

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

9 source entries across 9 studies. This list may not include all unresolved or historical entries.

  • Proparacaine OphthalmicRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Proxymetacaine 0.5%Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • proparacaineRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • ProparacaineRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • ProparacaineRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • ProparacaineRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • ProxymetacaineRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Topical SolutionRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Proparacaine OphthalmicRegistry intervention

    Molecular identity unconfirmed

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
50%(4 trials)

Phase Distribution

Not Applicable
7
78%
Phase 3
1
11%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 3Large-scale testing
1(12.5%)
N/ANon-phased studies
7(87.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(8)
Other(1)

Detailed Status

Completed8
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

Phase 31 (12.5%)
N/A7 (87.5%)

Trials by Status

completed889%
unknown111%

Recent Activity

Clinical Trials (9)

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
9

External References

Names & Codes

Trade Names

AK-TaineAlcaineChibro-KerakainKainairKéracaineMinims Proxymetacaine HydrochlorideOcu-CaineOphthaineOphtheticParcaineProparakain-POS

ATC Classification